로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Protein > Integrin alpha V beta 3 > IT3-H82W9

Biotinylated Human Integrin alpha V beta 3 (ITGAV&ITGB3) Heterodimer Protein, His,Avitag™&Tag Free

Recommended Hot Products:

Based on the high binding affinity between biotin-streptavidin systems, our Streptavidin series products are recommended to use together with biotinylated proteins to get lower non-specific binding results in a shorter time.

  • Synonym
    Integrin alpha V beta 3,ITGAV&ITGB3
  • Source
    Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free(IT3-H82W9) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 27 - Asp 718 (ITGB3) (Accession # P06756-1 (V783I) & P05106-1 ).
    Predicted N-terminus: Phe 31 (ITGAV) & Gly 27 (ITGB3)
  • Molecular Characterization
    Integrin alpha V beta 3 Structure

    Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His, Avitag™&Tag Free, produced by co-expression of ITGAV and ITGB3, has a calculated MW of 114.6 kDa (ITGAV) and 81.8 kDa (ITGB3). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB3 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 27 (ITGB3). The non-reducing (NR) protein migrates as 135 kDa (ITGAV) & 80 kDa (ITGB3) respectively due to glycosylation.

  • Labeling
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Integrin alpha V beta 3 SDS-PAGE

Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 Integrin alpha V beta 3 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB3 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT3-H82W9) with a linear range of 0.039-2.5 μg/mL (QC tested).

  • Background
    Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 525,000

가격(KRW) : 2,070,000

추천 제품
스트렙타비딘 코팅판

가격(KRW) : 48,000

가격(KRW) : 205,500

스트렙타비딘-HRP

가격(KRW) : 75,000

가격(KRW) : 180,000

Magnetic Beads™ 스트렙타비딘

가격(KRW) : 207,000

가격(KRW) : 345,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:24 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop